PE20040132A1 - Metodos y formas de dosificacion para la liberacion controlada de paliperidona - Google Patents
Metodos y formas de dosificacion para la liberacion controlada de paliperidonaInfo
- Publication number
- PE20040132A1 PE20040132A1 PE2003000749A PE2003000749A PE20040132A1 PE 20040132 A1 PE20040132 A1 PE 20040132A1 PE 2003000749 A PE2003000749 A PE 2003000749A PE 2003000749 A PE2003000749 A PE 2003000749A PE 20040132 A1 PE20040132 A1 PE 20040132A1
- Authority
- PE
- Peru
- Prior art keywords
- paliperidone
- capsule
- compartment
- nucleus
- compressed
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title abstract 7
- 229960001057 paliperidone Drugs 0.000 title abstract 7
- 239000002552 dosage form Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title 1
- 239000012530 fluid Substances 0.000 abstract 4
- 239000002775 capsule Substances 0.000 abstract 3
- 239000012528 membrane Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003204 osmotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UN METODO PARA TRATAR UNA ENFERMEDAD QUE RESPONDE A LA PALIPERIDONA, QUE COMPRENDE: 1)ADMINISTRAR POR VIA ORAL UNA FORMA DE DOSIFICACION CONSISTENTE EN UN NUCLEO COMPRIMIDO, EN FORMA DE CAPSULA, CONTENIENDO PALIPERIDONA, DONDE LA FORMA DE DOSIFICACION LIBERA LA PALIPERIDONA A UNA VELOCIDAD ASCENDENTE DURANTE UN PERIODO DE TIEMPO PROLONGADO. SE REFIERE A UNA FORMA DE DOSIFICACION, QUE COMPRENDE: 1)UN NUCLEO COMPRIMIDO EN FORMA DE CAPSULA, QUE CONTIENE UNA PLURALIDAD DE CAPAS, EN DONDE LA PALIPERIDONA, ESTA CONTENIDA EN AL MENOS UNA CAPA Y AL MENOS OTRA CAPA COMPRENDE UN POLIMERO EXPANSIBLE EN UN FLUIDO ADECUADO; b)UNA MEMBRANA SEMIPERMEABLE QUE RODEA EL NUCLEO COMPRIMIDO EN FORMA DE CAPSULA PARA FORMAR UN COMPARTIMIENTO QUE TIENE UN GRADIENTE OSMOTICO PARA CONDUCIR FLUIDO DESDE UN MEDIO FLUIDO EXTERNO QUE CONTACTA LA MEMBRANA DENTRO DEL COMPARTIMIENTO; c)UN ORIFICIO FORMADO A TRAVES DE (b) Y DENTRO DE (a) PARA PERMITIR QUE LA PALIPERIDONA SEA LIBERADA DESDE EL COMPARTIMIENTO AL MEDIO FLUIDO EXTERNO; Y, d)UNA SUBCUBIERTA PARA REDUCIR LA VELOCIDAD DE DEGRADACION DE LA PALIPERIDONA, QUE COMPRENDE UN POLIMERO HIDROXIALQUILCELULOSA DE PESO MOLECULAR APROXIMADO ENTRE 8 500 A 4 500 000, QUE AL MENOS RODEA PARCIALMENTE EL NUCLEO Y ESTA POSICIONADO ENTRE UNA SUPERFICIE INTERNA DE (b) Y (a)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39959002P | 2002-07-29 | 2002-07-29 | |
| US40600502P | 2002-08-26 | 2002-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040132A1 true PE20040132A1 (es) | 2004-03-06 |
Family
ID=31191280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000749A PE20040132A1 (es) | 2002-07-29 | 2003-07-30 | Metodos y formas de dosificacion para la liberacion controlada de paliperidona |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20040092534A1 (es) |
| EP (1) | EP1539115B1 (es) |
| JP (1) | JP4500679B2 (es) |
| KR (1) | KR100699516B1 (es) |
| CN (1) | CN1684670A (es) |
| AR (1) | AR040721A1 (es) |
| AT (1) | ATE373472T1 (es) |
| AU (1) | AU2003256844A1 (es) |
| BR (1) | BR0313139A (es) |
| CA (1) | CA2494234C (es) |
| CO (1) | CO5580742A2 (es) |
| CY (1) | CY1107096T1 (es) |
| DE (1) | DE60316454T2 (es) |
| DK (1) | DK1539115T3 (es) |
| ES (1) | ES2293039T3 (es) |
| HR (1) | HRP20050077B1 (es) |
| IL (1) | IL166489A (es) |
| MX (1) | MXPA05001191A (es) |
| MY (1) | MY137049A (es) |
| NO (1) | NO324821B1 (es) |
| NZ (1) | NZ570198A (es) |
| PE (1) | PE20040132A1 (es) |
| PL (1) | PL210119B1 (es) |
| PT (1) | PT1539115E (es) |
| RU (1) | RU2321391C2 (es) |
| TW (1) | TWI363637B (es) |
| WO (1) | WO2004010981A1 (es) |
| ZA (1) | ZA200501641B (es) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050232995A1 (en) * | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| AU2005271522B2 (en) * | 2004-08-04 | 2011-02-10 | Alza Corporation | Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition |
| WO2006085856A1 (en) * | 2005-02-04 | 2006-08-17 | Alza Corporation | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
| US20060189635A1 (en) * | 2005-02-04 | 2006-08-24 | Michelle Kramer | Enhanced efficacy benzisoxazole derivative dosage forms and methods |
| JP2009507774A (ja) * | 2005-08-04 | 2009-02-26 | アルザ・コーポレーシヨン | 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物 |
| WO2007081736A1 (en) * | 2006-01-06 | 2007-07-19 | Alza Corporation | Osmotic dosage form with controlled release and fast release aspects |
| SI3095447T1 (sl) | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
| US20070232624A1 (en) * | 2006-04-03 | 2007-10-04 | Palumbo Joseph M | Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients |
| CA2655499C (en) | 2006-06-21 | 2015-10-27 | Proventiv Therapeutics, Llc | Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies |
| US8524749B2 (en) * | 2007-02-09 | 2013-09-03 | Alza Corporation | Controlled release compositions of tizanidine |
| WO2009047644A2 (en) | 2007-04-25 | 2009-04-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| PL3542792T3 (pl) | 2007-04-25 | 2023-11-20 | Eirgen Pharma Ltd. | 25-hydroksywitamina d o kontrolowanym uwalnianiu |
| EP3225243B1 (en) * | 2007-04-25 | 2025-09-03 | Opko Renal, LLC | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| PL2079446T3 (pl) * | 2007-08-21 | 2012-04-30 | Teva Pharma | Preparat paliperidonu o przedłużonym uwalnianiu |
| BRPI0817946A2 (pt) | 2007-09-25 | 2015-05-05 | Teva Pharma | Composições de imatinibe estável |
| EP3909585A1 (en) * | 2007-12-19 | 2021-11-17 | Janssen Pharmaceutica NV | Dosing regimen associated with long acting injectable paliperidone esters |
| EP2280967A2 (en) * | 2008-03-27 | 2011-02-09 | Actavis Group PTC EHF | Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity |
| EP2326312A1 (en) * | 2008-07-25 | 2011-06-01 | KRKA, D.D., Novo Mesto | Paliperidone composition comprising solid matrix particles |
| EP2161019A1 (en) | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
| WO2010044097A2 (en) | 2008-09-15 | 2010-04-22 | Intas Pharmaceuticals Limited | Novel dosage form of paliperidone and process for preparing the same |
| CA2739181C (en) * | 2008-09-30 | 2017-03-14 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the delivery of risperidone and methods of use thereof |
| WO2011018246A2 (en) | 2009-08-13 | 2011-02-17 | Synthon B.V. | Controlled release paliperidone composition |
| US20110052687A1 (en) * | 2009-08-26 | 2011-03-03 | Glenmark Generics Ltd | Extended release pharmaceutical composition of paliperidone |
| CA2777856A1 (en) * | 2009-10-16 | 2011-04-21 | Ranbaxy Laboratories Limited | Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof |
| US9271939B2 (en) | 2010-03-15 | 2016-03-01 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
| RS60087B1 (sr) | 2010-03-29 | 2020-05-29 | Opko Ireland Global Holdings Ltd | Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona |
| ES2602503T3 (es) | 2010-04-22 | 2017-02-21 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
| US20120201886A1 (en) | 2010-07-30 | 2012-08-09 | Micro Labs Limited | Coated Extended Release Pharmaceutical Compositions Containing Paliperidone |
| CN102058517A (zh) * | 2010-12-31 | 2011-05-18 | 泰州万全医药科技有限公司 | 一种帕潘立酮缓释剂及其制备方法 |
| US20130034605A1 (en) | 2011-08-01 | 2013-02-07 | Micro Labs Limited | Extended release pharmaceutical compositions containing paliperidone |
| CN102274164B (zh) * | 2011-08-22 | 2014-07-02 | 长春健欣生物医药科技开发有限公司 | 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂 |
| US20150080404A1 (en) | 2012-04-14 | 2015-03-19 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| WO2014102741A2 (en) * | 2012-12-28 | 2014-07-03 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
| PT2968320T (pt) | 2013-03-15 | 2021-01-28 | Intra Cellular Therapies Inc | Compostos orgânicos |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| CN103271889B (zh) * | 2013-05-23 | 2015-10-28 | 沈阳药科大学 | 帕利哌酮新型递增释放渗透泵制剂及其制备方法 |
| CN103385857A (zh) * | 2013-06-29 | 2013-11-13 | 北京万全德众医药生物技术有限公司 | 帕利哌酮的药物组合物 |
| WO2015001488A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Extended-release tablets of paliperidone and processes of preparation thereof |
| KR102692169B1 (ko) | 2013-12-03 | 2024-08-05 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| ES2961843T3 (es) | 2014-04-04 | 2024-03-14 | Intra Cellular Therapies Inc | Gamma-carbolinas condensadas con heterociclo deuteradas como antagonistas de los receptores de 5-HT2A |
| CN106456638A (zh) | 2014-04-04 | 2017-02-22 | 细胞内治疗公司 | 有机化合物 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| US20160000654A1 (en) * | 2014-07-07 | 2016-01-07 | Cadila Healthcare Limited | Method for determining formulation orientation of asymmetric multi-layered osmotic tablets |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| CN104257622B (zh) * | 2014-10-01 | 2020-02-07 | 浙江华海药业股份有限公司 | 一种帕利哌酮控释片及其制备方法 |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| GR1008842B (el) | 2015-08-06 | 2016-09-05 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου |
| CN105147629B (zh) * | 2015-09-24 | 2017-08-25 | 吉林大学 | 一种异丁利酮片剂及制备方法 |
| HUE053737T2 (hu) | 2016-01-26 | 2021-07-28 | Intra Cellular Therapies Inc | Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik |
| KR102483124B1 (ko) | 2016-03-25 | 2022-12-29 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| AU2017253821B2 (en) | 2016-03-28 | 2022-11-03 | Opko Ireland Global Holdings, Limited | Methods of vitamin D treatment |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2017174096A1 (en) | 2016-04-05 | 2017-10-12 | Pharmathen S.A. | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018098115A1 (en) * | 2016-11-23 | 2018-05-31 | Children's Hospital Medical Center | Paliperidone for treatment of drug refractory irritability and autism spectrum disorder |
| CN106727392A (zh) * | 2016-12-15 | 2017-05-31 | 上海奕利制药有限公司 | 一种帕利哌酮缓释片剂及其制备方法 |
| WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| JP7132939B2 (ja) | 2017-03-24 | 2022-09-07 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規組成物および方法 |
| AU2018307479B2 (en) | 2017-07-26 | 2024-06-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| BR112020019181A2 (pt) | 2018-03-23 | 2021-01-05 | Intra-Cellular Therapies, Inc. | Compostos orgânicos |
| CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| US10695345B2 (en) | 2018-08-31 | 2020-06-30 | Intra-Cellular Therapies, Inc. | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
| KR102906995B1 (ko) | 2018-08-31 | 2025-12-31 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| EP3993798A4 (en) | 2019-07-07 | 2023-04-26 | Intra-Cellular Therapies, Inc. | NOVEL PROCESSES |
| KR102285510B1 (ko) | 2019-10-29 | 2021-08-04 | 강동국 | 양액 농도조절용 캡슐 및 그 용도 |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| CN113616610B (zh) * | 2021-07-30 | 2023-05-12 | 石药集团欧意药业有限公司 | 一种帕利哌酮缓释片及其制备方法 |
| US20230364009A1 (en) * | 2022-05-12 | 2023-11-16 | Celanese Eva Performance Polymers Llc | Implantable Medical Device for the Delivery of an Antipsychotic |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| CN120417904A (zh) | 2022-12-30 | 2025-08-01 | 细胞内治疗公司 | 作用于血清素5-HT2A受体的杂环稠合γ-咔啉 |
| WO2026011166A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor |
| WO2026011136A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656092A (en) * | 1985-10-15 | 1987-04-07 | R. P. Scherer Corporation | Target shooting capsules |
| GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| EP1029538A3 (en) * | 1993-09-28 | 2003-10-15 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| SK282231B6 (sk) * | 1993-11-19 | 2001-12-03 | Janssen Pharmaceutica N. V. | Farmaceutický prostriedok na liečenie psychotických porúch |
| TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| CA2263558A1 (en) * | 1996-08-16 | 1998-02-19 | Alza Corporation | Dosage form for providing ascending dose of drug |
| US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| WO1999062496A1 (en) * | 1998-06-03 | 1999-12-09 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| US6706282B1 (en) * | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
| DK1126853T3 (da) * | 1998-11-02 | 2006-08-14 | Alza Corp | Kontrolleret levering af antidepressine midler |
| CA2354472C (en) * | 1998-12-17 | 2009-02-24 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| ES2255490T3 (es) * | 1999-03-31 | 2006-07-01 | Janssen Pharmaceutica N.V. | Almidon pregelatinizado en una formulacion de liberacion controlada. |
| US6599532B2 (en) * | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
| US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
| US6375981B1 (en) * | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
| US6530962B1 (en) * | 2001-08-31 | 2003-03-11 | R.P. Scherer Technologies, Inc. | Emulsion of water soluble dyes in a lipophilic carrier |
-
2003
- 2003-07-28 PT PT03771910T patent/PT1539115E/pt unknown
- 2003-07-28 AT AT03771910T patent/ATE373472T1/de active
- 2003-07-28 KR KR1020057001460A patent/KR100699516B1/ko not_active Expired - Lifetime
- 2003-07-28 BR BR0313139-4A patent/BR0313139A/pt not_active Application Discontinuation
- 2003-07-28 ES ES03771910T patent/ES2293039T3/es not_active Expired - Lifetime
- 2003-07-28 DK DK03771910T patent/DK1539115T3/da active
- 2003-07-28 WO PCT/US2003/023433 patent/WO2004010981A1/en not_active Ceased
- 2003-07-28 DE DE60316454T patent/DE60316454T2/de not_active Expired - Lifetime
- 2003-07-28 RU RU2005102105/15A patent/RU2321391C2/ru not_active Application Discontinuation
- 2003-07-28 NZ NZ570198A patent/NZ570198A/en not_active IP Right Cessation
- 2003-07-28 EP EP03771910A patent/EP1539115B1/en not_active Revoked
- 2003-07-28 PL PL376258A patent/PL210119B1/pl unknown
- 2003-07-28 AU AU2003256844A patent/AU2003256844A1/en not_active Abandoned
- 2003-07-28 CN CNA03822948XA patent/CN1684670A/zh active Pending
- 2003-07-28 US US10/629,211 patent/US20040092534A1/en not_active Abandoned
- 2003-07-28 JP JP2004524886A patent/JP4500679B2/ja not_active Expired - Lifetime
- 2003-07-28 HR HRP20050077AA patent/HRP20050077B1/hr not_active IP Right Cessation
- 2003-07-28 CA CA002494234A patent/CA2494234C/en not_active Expired - Lifetime
- 2003-07-28 MX MXPA05001191A patent/MXPA05001191A/es active IP Right Grant
- 2003-07-29 TW TW092120703A patent/TWI363637B/zh not_active IP Right Cessation
- 2003-07-29 MY MYPI20032846A patent/MY137049A/en unknown
- 2003-07-29 AR AR20030102717A patent/AR040721A1/es unknown
- 2003-07-30 PE PE2003000749A patent/PE20040132A1/es not_active Application Discontinuation
-
2005
- 2005-01-25 IL IL166489A patent/IL166489A/en active IP Right Grant
- 2005-02-22 NO NO20050956A patent/NO324821B1/no not_active IP Right Cessation
- 2005-02-24 ZA ZA2005/01641A patent/ZA200501641B/en unknown
- 2005-02-28 CO CO05018509A patent/CO5580742A2/es not_active Application Discontinuation
-
2007
- 2007-12-18 CY CY20071101601T patent/CY1107096T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040132A1 (es) | Metodos y formas de dosificacion para la liberacion controlada de paliperidona | |
| Su et al. | A water-powered micro drug delivery system | |
| ES2507668T3 (es) | Reloj en tiempo real virtual en base a información de tiempo procedente de múltiples sistemas de comunicación | |
| ECSP088640A (es) | Método y sistema para el mantenimiento de una membrana usada para osmosis retardada con presión | |
| PE20040131A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| AR041562A1 (es) | Preparacion de liberacion controlada | |
| CY1107727T1 (el) | Οσμωτικη ενεργεια | |
| AR047698A1 (es) | Reductor de ritmo de imbibicion modular para usar con bomba osmotica implantable | |
| BRPI0919884B8 (pt) | cateter de perfusão de oclusão | |
| AR033943A1 (es) | Un dispositivo para la liberacion controlada de agentes activos a un ambiente de uso | |
| AR083524A1 (es) | Cartucho de fluido; estructura de recepcion de cartucho de fluido, dispositivo inyector de fluido, sistema de expulsion de fluido y metodo para conectar un cartucho de fluido | |
| AR063135A1 (es) | Sistema dosificador de medicamento por medio de una microbomba | |
| AR060176A1 (es) | Procedimiento y dispositivo para la preparacion de una bebida bajo presion controlada | |
| CO6280400A2 (es) | Inhibidores de la enzima integrasa vih y composiciones farmaceuticas que contienen dichos compuestos | |
| ATE527046T1 (de) | Verfahren zur abtrennung magnetischer partikelfraktionen durch eine semipermeable membran | |
| AR116315A1 (es) | Compuestos de triazolo-pirimidina y usos de los mismos | |
| AR063253A1 (es) | Sistema y procedimiento para detectar la posicion de una cabina de ascensor | |
| AR067497A1 (es) | Sistemas y metodos para separar hidrocarburos de agua | |
| BR112012020402A2 (pt) | aparelho, sistema e método para liberar fluidos de um riser submarino | |
| CL2012002787A1 (es) | Sistema de irrigacion, en que los medios de irrigacion se pueden acomodar con mayor facilidad en un medio de crecimiento, evitando filtracion de contaminantes por la rotura o agrietamiento del sistema de irrigacion, y que comprende una membrana hidrofila tubular no porosa y helicoidal enterrada en dicho medio de crecimiento; y metodo de irrigacion | |
| CL2016000385A1 (es) | Sistema y método para separación física de partículas de diferentes tamaños y/o material dentro de una masa aglomerada en suspensión, que comprende un medio flexible de filtración selectiva y un vibrador que hace vibrar el medio flexible en ubicaciones discretas sobre la cara exterior de éste. | |
| AR241635A1 (es) | Dispositivo osmotico para la administracion de una droga a regimen de liberacion dosificado. | |
| PE20030801A1 (es) | Sistema de suministro osmotico | |
| AR089765A1 (es) | Un sistema para el suministro de un farmaco | |
| MXPA05002450A (es) | Metodo para suministrar esterilizante liquido a un esterilizador. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |